Biotechnology
Compare Stocks
2 / 10Stock Comparison
AMRN vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
AMRN vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $309M | $1.61B |
| Revenue (TTM) | $215M | $4.18B |
| Net Income (TTM) | $-34M | $-1.82B |
| Gross Margin | 52.5% | 34.2% |
| Operating Margin | -17.4% | -4.1% |
| Forward P/E | — | 5.6x |
| Total Debt | $12M | $3.97B |
| Cash & Equiv. | $135M | $532M |
AMRN vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Amarin Corporation … (AMRN) | 100 | 10.8 | -89.2% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMRN vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AMRN carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.94
- -54.5% 10Y total return vs PRGO's -77.7%
- Lower volatility, beta 0.94, Low D/E 2.6%, current ratio 3.34x
PRGO is the clearest fit if your priority is growth exposure.
- Rev growth -2.8%, EPS growth -7.2%, 3Y rev CAGR -1.5%
- -2.8% revenue growth vs AMRN's -6.5%
- Better valuation composite
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -2.8% revenue growth vs AMRN's -6.5% | |
| Value | Better valuation composite | |
| Quality / Margins | -15.6% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 0.94 vs PRGO's 1.18, lower leverage | |
| Dividends | 9.8% yield; 10-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +45.8% vs PRGO's -51.2% | |
| Efficiency (ROA) | -5.1% ROA vs PRGO's -19.8%, ROIC -2.9% vs 3.7% |
AMRN vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AMRN vs PRGO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
AMRN leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 19.4x AMRN's $215M. AMRN is the more profitable business, keeping -15.6% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, AMRN holds the edge at +3.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $215M | $4.2B |
| EBITDAEarnings before interest/tax | -$34M | $58M |
| Net IncomeAfter-tax profit | -$34M | -$1.8B |
| Free Cash FlowCash after capex | $26M | $108M |
| Gross MarginGross profit ÷ Revenue | +52.5% | +34.2% |
| Operating MarginEBIT ÷ Revenue | -17.4% | -4.1% |
| Net MarginNet income ÷ Revenue | -15.6% | -43.5% |
| FCF MarginFCF ÷ Revenue | +11.9% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.1% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +32.9% | -56.4% |
Valuation Metrics
PRGO leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $309M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $186M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -8.24x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 1.44x | 0.38x |
| Price / BookPrice ÷ Book value/share | 0.67x | 0.55x |
| Price / FCFMarket cap ÷ FCF | 45.77x | 11.12x |
Profitability & Efficiency
AMRN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
AMRN delivers a -7.3% return on equity — every $100 of shareholder capital generates $-7 in annual profit, vs $-51 for PRGO. AMRN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), AMRN scores 5/9 vs PRGO's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -7.3% | -50.7% |
| ROA (TTM)Return on assets | -5.1% | -19.8% |
| ROICReturn on invested capital | -2.9% | +3.7% |
| ROCEReturn on capital employed | -2.8% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 1.35x |
| Net DebtTotal debt minus cash | -$123M | $3.4B |
| Cash & Equiv.Liquid assets | $135M | $532M |
| Total DebtShort + long-term debt | $12M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | -5148.71x | -7.20x |
Total Returns (Dividends Reinvested)
AMRN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRGO five years ago would be worth $3,986 today (with dividends reinvested), compared to $1,613 for AMRN. Over the past 12 months, AMRN leads with a +45.8% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors AMRN at -17.7% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +8.2% | -13.5% |
| 1-Year ReturnPast 12 months | +45.8% | -51.2% |
| 3-Year ReturnCumulative with dividends | -44.2% | -58.1% |
| 5-Year ReturnCumulative with dividends | -83.9% | -60.1% |
| 10-Year ReturnCumulative with dividends | -54.5% | -77.7% |
| CAGR (3Y)Annualised 3-year return | -17.7% | -25.2% |
Risk & Volatility
AMRN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AMRN is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMRN currently trades 71.0% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.94x | 1.18x |
| 52-Week HighHighest price in past year | $20.90 | $28.44 |
| 52-Week LowLowest price in past year | $9.44 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +71.0% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 55.8 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 71K | 3.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates AMRN as "Hold" and PRGO as "Hold". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs -85.4% for AMRN (target: $2). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | $2.17 | $20.00 |
| # AnalystsCovering analysts | 18 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | +9.8% |
| Dividend StreakConsecutive years of raises | — | 10 |
| Dividend / ShareAnnual DPS | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
AMRN leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 1 (Valuation Metrics).
AMRN vs PRGO: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is AMRN or PRGO a better buy right now?
For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.
8% revenue growth year-over-year, versus -6. 5% for Amarin Corporation plc (AMRN). Analysts rate Amarin Corporation plc (AMRN) a "Hold" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AMRN or PRGO?
Over the past 5 years, Perrigo Company plc (PRGO) delivered a total return of -60.
1%, compared to -83. 9% for Amarin Corporation plc (AMRN). Over 10 years, the gap is even starker: AMRN returned -54. 5% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AMRN or PRGO?
By beta (market sensitivity over 5 years), Amarin Corporation plc (AMRN) is the lower-risk stock at 0.
94β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 25% more volatile than AMRN relative to the S&P 500. On balance sheet safety, Amarin Corporation plc (AMRN) carries a lower debt/equity ratio of 3% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
04Which is growing faster — AMRN or PRGO?
By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.
8% versus -6. 5% for Amarin Corporation plc (AMRN). On earnings-per-share growth, the picture is similar: Amarin Corporation plc grew EPS 55. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PRGO leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AMRN or PRGO?
Amarin Corporation plc (AMRN) is the more profitable company, earning -18.
2% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps -18. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -6. 5% for AMRN. At the gross margin level — before operating expenses — AMRN leads at 56. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is AMRN or PRGO more undervalued right now?
Analyst consensus price targets imply the most upside for PRGO: 70.
6% to $20. 00.
07Which pays a better dividend — AMRN or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. AMRN does not pay a meaningful dividend and should not be held primarily for income.
08Is AMRN or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 8% yield). Both have compounded well over 10 years (PRGO: -77. 7%, AMRN: -54. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between AMRN and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AMRN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while AMRN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.